Y-mAbs Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Gain from sale of priority review voucher, net
Depreciation and amortization
Stock-based compensation
Non-cash expense in connection with equity issuance to MSK/MIT
Non-cash expense in connection with equity issuance to inventors
Foreign currency transactions
Foreign currency and other transactions
Provision for bad debt
Changes in assets and liabilities:
Accounts receivable, net
Inventories
Other current assets
Inventories, long-term
Other assets
Accounts payable
Accrued liabilities and other

NET CASH USED IN OPERATING ACTIVITIES
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment
Acquisition of intangible assets
Loans to inventors
Net proceeds from sale of priority review voucher
NET CASH PROVIDED BY INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock, net of issuance costs
Proceeds from exercised stock options
NET CASH PROVIDED BY FINANCING ACTIVITIES

Effect of exchange rates on cash and cash equivalents
NET DECREASE IN CASH AND CASH EQUIVALENTS
Cash and cash equivalents at the beginning of period
Cash and cash equivalents at the end of period
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for income taxes
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES
Intangible assets acquisition in accrued liabilities
Right-of-use assets obtained in exchange for lease obligations
Acquisition of treasury shares upon repayment of secured promissory note

Comments